Drug Type CAR-T |
Synonyms αvβ3/HER2 bispecific CAR-T(University of Virginia) |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Childhood Rhabdomyosarcoma | Preclinical | United States | 07 Nov 2022 |